The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has a clear sex
disparity in clinical outcomes. Hence, the interaction between sex hormones, virus entry …

Importance SARS-CoV-2 entry requires the TMPRSS2 cell surface protease. Antiandrogen
therapies reduce expression of TMPRSS2. Objective To determine if temporary androgen …

Abstract The coronavirus disease 2019 (COVID‐19) pandemic has created unprecedented
challenges worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) …

The current epidemic of corona virus disease (COVID-19) has resulted in an immense
health burden that became the third leading cause of death and potentially contributed to a …

There is overwhelming evidence to suggest that male gender is at a higher risk of
developing more severe Covid‐19 disease and thus having poorer clinical outcomes …

Importance Male sex is associated with severe COVID-19. It is not known whether the risk of
hospitalization differs between men with hypogonadism, men with eugonadism, and those …

Objective Men are at greater risk from COVID-19 than women. Older, overweight men, and
those with type 2 diabetes, have lower testosterone concentrations and poorer COVID-19 …

Antiandrogens may carry a potential benefit as a therapeutic agent against COVID‐19.
However, studies have been yielding mixed results, thus hindering any objective …

On 11 March 2020, the WHO declared the coronavirus disease 2019 (COVID-19) outbreak a
pandemic and COVID-19 emerged as one of the biggest challenges in public health and …